VaxGen AIDSVAX BLA Slated For 2004 While Manufacturing Work Is Finished
Executive Summary
VaxGen is pushing back its BLA filing for the AIDS vaccine AIDSVAX until 2004 while it works to fulfill pre-approval manufacturing requirements
You may also be interested in...
VaxGen AIDSVAX Hopes Hinge On Positive Finding In Small Subgroups
VaxGen is pinning its hopes for the continued development of AIDSVAX on a positive finding in a small subgroup of black and Asian HIV patients after disappointing Phase III efficacy results in the general high-risk HIV population
VaxGen AIDSVAX Hopes Hinge On Positive Finding In Small Subgroups
VaxGen is pinning its hopes for the continued development of AIDSVAX on a positive finding in a small subgroup of black and Asian HIV patients after disappointing Phase III efficacy results in the general high-risk HIV population
VaxGen IPO Could Allow For Completion of AIDS Vaccine Phase III Trials
VaxGen plans to meet the 2002 deadline for an AIDS vaccine NDA submission set by marketing partner Genentech with the help of an initial public offering of 3.1 mil. shares.